Related references
Note: Only part of the references are listed.Diosmin downregulates the expression of T cell receptors, pro-inflammatory cytokines and NF-κB activation against LPS-induced acute lung injury in mice
Faisal Imam et al.
PHARMACOLOGICAL RESEARCH (2015)
Mitogen-Activated Protein Kinases Pathways Mediate the Sunitinib-Induced Hypertrophy in Rat Cardiomyocyte H9c2 Cells
Hesham Mohamed Korashy et al.
CARDIOVASCULAR TOXICOLOGY (2015)
Naringin Attenuates the Development of Carrageenan-Induced Acute Lung Inflammation Through Inhibition of NF-κb, STAT3 and Pro-Inflammatory Mediators and Enhancement of IκBα and Anti-Inflammatory Cytokines
Sheikh Fayaz Ahmad et al.
INFLAMMATION (2015)
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
Ajai Chari et al.
BMC CANCER (2014)
Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren
Naif O. Al-Harbi et al.
TOXICOLOGY MECHANISMS AND METHODS (2014)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
Thomas M. Herndon et al.
CLINICAL CANCER RESEARCH (2013)
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel et al.
HAEMATOLOGICA (2013)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
Roman Hajek et al.
BMC CANCER (2012)
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Ravi Vij et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Quercetin Ameliorates Cardiovascular, Hepatic, and Metabolic Changes in Diet-Induced Metabolic Syndrome in Rats
Sunil K. Panchal et al.
JOURNAL OF NUTRITION (2012)
Desferrioxamine Attenuates Doxorubicin-Induced Acute Cardiotoxicity through TFG-β/Smad p53 Pathway in Rat Model
Othman A. Al-Shabanah et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2012)
Role of carfilzomib in the treatment of multiple myeloma
Rashid Z. Khan et al.
EXPERT REVIEW OF HEMATOLOGY (2012)
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
Jinfu Yang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats
Azhar Rashikh et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2011)
Rutin Attenuates Metabolic Changes, Nonalcoholic Steatohepatitis, and Cardiovascular Remodeling in High-Carbohydrate, High-Fat Diet-Fed Rats
Sunil K. Panchal et al.
JOURNAL OF NUTRITION (2011)
被撤回的出版物: Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure (Retracted article. See vol. 117, pg. 2821, 2021)
Biswajit Das et al.
CARDIOVASCULAR RESEARCH (2010)
Cardioprotective Effect of Ficus hispida Linn. on Cyclophosphamide Provoked Oxidative Myocardial Injury in a Rat Model
T.S. Shanmugarajan et al.
International Journal of Pharmacology (2009)
Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity
Mohamed A. Ibrahim et al.
PHARMACOLOGICAL RESEARCH (2009)
The NF-κB Family of Transcription Factors and Its Regulation
Andrea Oeckinghaus et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity
Ho Sup Lee et al.
Cancer Research and Treatment (2009)
Molecular regulation of cardiac hypertrophy
Sean P. Barry et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Update on uses and properties of Citrus flavonolds:: New findings in anticancer, cardiovascular, and anti-inflammatory activity
O. Benavente-Garcia et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2008)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Good cop, bad cop:: the different faces of NF-κB
ND Perkins et al.
CELL DEATH AND DIFFERENTIATION (2006)
NF-κB activation as a pathological mechanism of septic shock and inflammation
SF Liu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy:: an innocent bystander?
A Repetto et al.
EUROPEAN HEART JOURNAL (2005)
Vascular NADPH oxidases: molecular mechanisms of activation
RP Brandes et al.
CARDIOVASCULAR RESEARCH (2005)
Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells
HM Korashy et al.
TOXICOLOGY (2004)
Cardiovascular complications of cancer therapy - Diagnosis, pathogenesis, and management
ETH Yeh et al.
CIRCULATION (2004)
Erdosteine prevents doxorubicin-induced cardiotoxicity in rats
M Yagmurca et al.
PHARMACOLOGICAL RESEARCH (2003)
Clinical applications of B-type natriuretic peptide (BNP) testing
MR Cowie et al.
EUROPEAN HEART JOURNAL (2003)
P53 stabilization is decreased upon NFκB activation:: A role for NFκB in acquisition of resistance to chemotherapy
V Tergaonkar et al.
CANCER CELL (2002)
Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats
MA El-Missiry et al.
FREE RADICAL RESEARCH (2001)
Myosin heavy chain isoform expression in the failing and nonfailing human heart
S Miyata et al.
CIRCULATION RESEARCH (2000)
Share Paper
